Veterinary Stereotactic Radiosurgery System Market - Global Forecast 2025-2032

The Veterinary Stereotactic Radiosurgery System Market is entering a period of rapid advancement driven by technology adoption and shifting clinical priorities in veterinary oncology. Precision cancer therapies for companion animals are fast becoming the core standard of care, presenting new opportunities and operational considerations for veterinary providers and industry stakeholders.

Market Snapshot: Veterinary Stereotactic Radiosurgery System Market Growth

The Veterinary Stereotactic Radiosurgery System Market grew from USD 628.31 million in 2024 to USD 715.82 million in 2025. It is projected to maintain strong momentum with a CAGR of 13.62% through 2032, reaching USD 1.74 billion. This growth is closely linked to increased demand for minimally invasive, high-precision animal cancer therapies.

Scope & Segmentation

This research delivers a multidimensional analysis of the veterinary stereotactic radiosurgery space, covering product variations, technological options, and major end-user segments across key regions.

• Product Type: CyberKnife systems, Gamma Knife systems, Linear Accelerators (LINACs), Proton Therapy Systems
• Technology: Image-Guided Radiosurgery (IGRS), Intensity-Modulated Radiosurgery (IMRS), Stereotactic Body Radiation Therapy (SBRT), Volumetric Modulated Arc Therapy (VMAT)
• Animal Type: Canine, Equine, Feline
• Treatment Modality: Fractionated, Single-Session
• End User: Research Institutes, Specialty Clinics, Veterinary Hospitals
• Geography: Americas (United States, Canada, Mexico, Brazil, Argentina, Chile, Colombia, Peru), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland, United Arab Emirates, Saudi Arabia, Qatar, Turkey, Israel, South Africa, Nigeria, Egypt, Kenya), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan)
• Key Companies: Accuray Incorporated, Elekta AB, Nanovi A/S, Xstrahl Group, PetCure Oncology, Varian Medical Systems, Inc., Eckert & Ziegler Radiopharma GmbH, Merck & Co., Inc., Vision RT Ltd., ZAP Surgical Systems, Inc.

Key Takeaways

• Veterinary stereotactic radiosurgery achieves high-dose, targeted cancer treatments with sub-millimeter accuracy, reducing collateral tissue impact.
• Newer modalities integrate image guidance and advanced dose modulation, supporting personalized adaptive therapies matched to animal anatomy and tumor characteristics.
• The shift to non-invasive, high-precision technologies enhances patient comfort, creating efficiency gains and faster recoveries for companion animals across broad clinical settings.
• Specialty veterinary clinics and research institutes are collaborating with technology providers, driving broader access and rapid systems uptake in both established and emerging markets.
• Software-driven planning platforms and machine learning algorithms in radiosurgery foster data-driven, agile treatment workflows and ongoing improvements to patient outcomes.
• Segmented analysis clarifies unique operational needs for canine, equine, and feline applications—enabling decision-makers to target investments based on practice profile and clinical mix.

Tariff Impact: Navigating Shifting Cost Structures

Anticipated tariff changes in the United States for 2025 pose several considerations for procurement teams and system manufacturers. Increased import duties on international components may alter capital expenditure timelines and spark a renewed focus on domestic production partnerships. Clinics and research centers are reviewing contract structures, supply chain contingencies, and bundled maintenance or upgrade agreements as strategies to mitigate cost volatility, ensure asset longevity, and protect against logistical disruptions. Early equipment acquisitions are being considered to take advantage of pre-tariff pricing and maintain uninterrupted technology implementation schedules.

Methodology & Data Sources

This report is built on an integrated methodology combining primary interviews with subject matter experts and secondary analysis of industry literature, regulatory filings, and market data. Key findings are validated through data triangulation and verified by senior research analysts, supporting the reliability of actionable insights.

Why This Report Matters

• Provides senior decision-makers with structured, evidence-based analysis of the veterinary radiosurgery landscape to support technology planning and capital allocation.
• Enables strategy development through detailed segmentation across technology, animal type, and end user, ensuring relevance to diverse clinical practice models.
• Assists in navigating supply chain changes, regulatory environments, and partnership opportunities for sustainable operational decisions in a growing and competitive market.

Conclusion

The veterinary stereotactic radiosurgery system market is shaped by rapid technological innovation, clinical collaboration, and evolving operational strategies. Stakeholders equipped with detailed insights will be better positioned to adapt, invest wisely, and lead in delivering effective precision oncology solutions for animal health.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.